Capricor Retained Earnings from 2010 to 2024

CAPR Stock

USD 18.62 0.83 4.67%

Capricor Therapeutics Retained Earnings yearly trend continues to be relatively stable with very little volatility. Retained Earnings are likely to grow to about -151.4 M this year. Retained Earnings is the cumulative amount of net income that Capricor Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2001-12-31

Previous Quarter

-180.2 M

Current Value

-192.7 M

Quarterly Volatility

15.9 B

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Capricor Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Capricor Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 2 M or Other Operating Expenses of 51.7 M, as well as many indicators such as Price To Sales Ratio of 4.94, Dividend Yield of 0.0 or PTB Ratio of 6.08. Capricor financial statements analysis is a perfect complement when working with Capricor Therapeutics Valuation or Volatility modules.

Check out the analysis of Capricor Therapeutics Correlation against competitors.

To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.

Latest Capricor Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Capricor Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Capricor Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Capricor Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (159.37 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Capricor Retained Earnings Regression Statistics

	Arithmetic Mean	(70,380,049)
	Coefficient Of Variation	(70.00)
	Mean Deviation	39,472,617
	Median	(53,979,242)
	Standard Deviation	49,265,784
	Sample Variance	2427.1T
	Range	159.4M
	R-Value	(0.93)
	Mean Square Error	374.3T
	R-Squared	0.86
	Slope	(10,196,972)
	Total Sum of Squares	33979.6T

Capricor Retained Earnings History

	2024	-151.4 M
	2023	-159.4 M
	2022	-137.1 M
	2021	-108.1 M
	2020	-88 M
	2019	-74.4 M
	2018	-66.7 M

Other Fundumenentals of Capricor Therapeutics

Retained Earnings Total Equity

Capricor Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Accounts Payable	Total Liab	Common Stock	Net Debt	Net Receivables	Total Current Assets	Short Term Debt	Intangible Assets	Net Tangible Assets	Long Term Debt	Short Term Investments	Capital Surpluse	Property Plant Equipment	Accumulated Depreciation	Current Deferred Revenue	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.78	-0.93	0.97	0.83	0.11	-0.59	0.74	1.0	-0.43	-0.13	0.56	0.03	0.78	0.92	0.94	0.68	0.68	-0.48	-0.62	0.63	0.63	-0.18
Total Stockholder Equity	0.78		-0.78	0.64	0.3	0.16	-0.89	0.49	0.79	-0.62	-0.05	0.92	-0.38	0.3	0.87	0.74	0.45	0.23	-0.71	-0.79	0.84	0.82	-0.36
Retained Earnings	-0.93	-0.78		-0.87	-0.72	-0.33	0.52	-0.72	-0.92	0.44	-0.03	-0.58	0.12	-0.76	-0.96	-0.91	-0.68	-0.63	0.58	0.72	-0.51	-0.5	0.3
Accounts Payable	0.97	0.64	-0.87		0.91	0.11	-0.45	0.79	0.96	-0.29	-0.13	0.39	0.19	0.83	0.84	0.91	0.72	0.75	-0.31	-0.46	0.53	0.51	-0.05
Total Liab	0.83	0.3	-0.72	0.91		0.03	-0.11	0.7	0.82	-0.11	-0.16	0.04	0.37	0.92	0.64	0.77	0.63	0.82	-0.1	-0.24	0.22	0.24	0.04
Common Stock	0.11	0.16	-0.33	0.11	0.03		-0.13	0.13	0.11	0.21	0.16	0.14	-0.21	0.1	0.2	0.17	0.18	0.14	-0.1	-0.1	0.1	0.08	0.35
Net Debt	-0.59	-0.89	0.52	-0.45	-0.11	-0.13		-0.17	-0.62	0.47	0.15	-0.93	0.22	-0.04	-0.62	-0.49	-0.16	0.08	0.51	0.59	-0.9	-0.91	0.25
Net Receivables	0.74	0.49	-0.72	0.79	0.7	0.13	-0.17		0.73	-0.26	-0.08	0.13	-0.05	0.67	0.7	0.74	0.95	0.83	-0.28	-0.38	0.34	0.21	0.03
Total Current Assets	1.0	0.79	-0.92	0.96	0.82	0.11	-0.62	0.73		-0.43	-0.13	0.58	0.03	0.76	0.92	0.92	0.66	0.65	-0.47	-0.62	0.65	0.65	-0.19
Short Term Debt	-0.43	-0.62	0.44	-0.29	-0.11	0.21	0.47	-0.26	-0.43		-0.25	-0.58	0.47	-0.24	-0.57	-0.42	-0.23	-0.11	0.83	0.8	-0.28	-0.28	0.39
Intangible Assets	-0.13	-0.05	-0.03	-0.13	-0.16	0.16	0.15	-0.08	-0.13	-0.25		-0.02	-0.06	-0.11	0.0	-0.09	-0.08	-0.22	-0.29	-0.31	-0.34	-0.37	0.03
Net Tangible Assets	0.56	0.92	-0.58	0.39	0.04	0.14	-0.93	0.13	0.58	-0.58	-0.02		-0.4	0.05	0.68	0.55	0.14	-0.09	-0.67	-0.72	0.82	0.83	-0.39
Long Term Debt	0.03	-0.38	0.12	0.19	0.37	-0.21	0.22	-0.05	0.03	0.47	-0.06	-0.4		0.2	-0.25	-0.09	-0.08	-0.04	0.62	0.46	-0.2	-0.2	0.18
Short Term Investments	0.78	0.3	-0.76	0.83	0.92	0.1	-0.04	0.67	0.76	-0.24	-0.11	0.05	0.2		0.68	0.74	0.61	0.83	-0.22	-0.36	0.06	0.09	-0.05
Capital Surpluse	0.92	0.87	-0.96	0.84	0.64	0.2	-0.62	0.7	0.92	-0.57	0.0	0.68	-0.25	0.68		0.92	0.65	0.59	-0.63	-0.76	0.61	0.6	-0.33
Property Plant Equipment	0.94	0.74	-0.91	0.91	0.77	0.17	-0.49	0.74	0.92	-0.42	-0.09	0.55	-0.09	0.74	0.92		0.68	0.71	-0.5	-0.6	0.58	0.57	-0.13
Accumulated Depreciation	0.68	0.45	-0.68	0.72	0.63	0.18	-0.16	0.95	0.66	-0.23	-0.08	0.14	-0.08	0.61	0.65	0.68		0.78	-0.29	-0.34	0.35	0.18	0.08
Current Deferred Revenue	0.68	0.23	-0.63	0.75	0.82	0.14	0.08	0.83	0.65	-0.11	-0.22	-0.09	-0.04	0.83	0.59	0.71	0.78		-0.12	-0.17	0.13	0.11	0.16
Long Term Debt Total	-0.48	-0.71	0.58	-0.31	-0.1	-0.1	0.51	-0.28	-0.47	0.83	-0.29	-0.67	0.62	-0.22	-0.63	-0.5	-0.29	-0.12		0.96	-0.33	-0.33	0.44
Short Long Term Debt	-0.62	-0.79	0.72	-0.46	-0.24	-0.1	0.59	-0.38	-0.62	0.8	-0.31	-0.72	0.46	-0.36	-0.76	-0.6	-0.34	-0.17	0.96		-0.38	-0.38	0.5
Net Invested Capital	0.63	0.84	-0.51	0.53	0.22	0.1	-0.9	0.34	0.65	-0.28	-0.34	0.82	-0.2	0.06	0.61	0.58	0.35	0.13	-0.33	-0.38		0.96	-0.13
Net Working Capital	0.63	0.82	-0.5	0.51	0.24	0.08	-0.91	0.21	0.65	-0.28	-0.37	0.83	-0.2	0.09	0.6	0.57	0.18	0.11	-0.33	-0.38	0.96		-0.17
Capital Stock	-0.18	-0.36	0.3	-0.05	0.04	0.35	0.25	0.03	-0.19	0.39	0.03	-0.39	0.18	-0.05	-0.33	-0.13	0.08	0.16	0.44	0.5	-0.13	-0.17

Click cells to compare fundamentals

About Capricor Therapeutics Financial Statements

Capricor Therapeutics shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Capricor Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Capricor Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Capricor Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-159.4 M	-151.4 M
Retained Earnings Total Equity	-123.4 M	-117.2 M

Pair Trading with Capricor Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Capricor Stock

0.87	NKTX	Nkarta Inc	Pair Corr
0.79	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.76	VALN	Valneva SE ADR	Pair Corr
0.76	CYRX	Cryoport	Pair Corr
0.72	MTEM	Molecular Templates	Pair Corr

The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.

The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Capricor Stock Analysis

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC